Search research articles
Contact Us
Filters
Showing results (21-30 of 143) with videos related to
Page
of 15
Sort By:
The Oncologist
|
August 8, 2018
Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors
Santosha Vardhana, Kara Cicero, Moises J Velez, et al.
Nature Reviews. Clinical Oncology
|
July 17, 2023
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime
Juan Pablo Alderuccio, Russ A Kuker, Fei Yang, et al.
Clinical Advances in Hematology & Oncology : H&O
|
October 3, 2015
Managing Risk in Hodgkin Lymphoma
James O Armitage, Robert W Chen, Craig H Moskowitz, et al.
Expert Review of Hematology
|
March 16, 2019
Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma
Parastoo B Dahi, Craig H Moskowitz, Sergio A Giralt, et al.
Expert Review of Hematology
|
March 19, 2019
Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma
Parastoo B Dahi, Craig H Moskowitz, Sergio A Giralt, et al.
JAMA Dermatology
|
November 22, 2013
Disseminated mantle-cell lymphoma presenting as a petechial maculopapular eruption
Sarah I Jawed, Travis J Hollmann, Craig H Moskowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 24, 2008
Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma
Karyn A Goodman, Elyn Riedel, Victoria Serrano, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 22, 2022
Prognostic Value of <sup>18</sup>F-FDG PET/CT in Diffuse Large B-Cell Lymphoma Treated with a Risk-Adapted Immunochemotherapy Regimen
Laure Michaud, Kurt Bantilan, Audrey Mauguen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 20, 2013
False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma
Gary A Ulaner, Joshua Lilienstein, Mithat Gönen, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM
|
August 25, 2009
High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin lymphoma
Daniel O Persky, Craig H Moskowitz, Alexander Filatov, et al.
Page
of 15
Search research articles
Search
Showing results (21-30 of 143) with videos related to
Sort By:
Page
of 15
The Oncologist
|
August 8, 2018
Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors
Santosha Vardhana, Kara Cicero, Moises J Velez, et al.
Nature Reviews. Clinical Oncology
|
July 17, 2023
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime
Juan Pablo Alderuccio, Russ A Kuker, Fei Yang, et al.
Clinical Advances in Hematology & Oncology : H&O
|
October 3, 2015
Managing Risk in Hodgkin Lymphoma
James O Armitage, Robert W Chen, Craig H Moskowitz, et al.
Expert Review of Hematology
|
March 16, 2019
Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma
Parastoo B Dahi, Craig H Moskowitz, Sergio A Giralt, et al.
Expert Review of Hematology
|
March 19, 2019
Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma
Parastoo B Dahi, Craig H Moskowitz, Sergio A Giralt, et al.
JAMA Dermatology
|
November 22, 2013
Disseminated mantle-cell lymphoma presenting as a petechial maculopapular eruption
Sarah I Jawed, Travis J Hollmann, Craig H Moskowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 24, 2008
Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma
Karyn A Goodman, Elyn Riedel, Victoria Serrano, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 22, 2022
Prognostic Value of <sup>18</sup>F-FDG PET/CT in Diffuse Large B-Cell Lymphoma Treated with a Risk-Adapted Immunochemotherapy Regimen
Laure Michaud, Kurt Bantilan, Audrey Mauguen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 20, 2013
False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma
Gary A Ulaner, Joshua Lilienstein, Mithat Gönen, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM
|
August 25, 2009
High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin lymphoma
Daniel O Persky, Craig H Moskowitz, Alexander Filatov, et al.
Page
of 15